Please provide your email address to receive an email when new articles are posted on . Graeme Jones, PhD, and colleagues randomly assigned 223 patients with symptomatic knee OA and subchondral bone ...

The efficacy of zoledronic acid after hip fracture was evaluated in 2,127 patients (1,619 women and 508 men) aged 50 years and older (N Engl J Med. 2007;357:1799-1809). The Health Outcomes and Reduced ...

Please provide your email address to receive an email when new articles are posted on . “Discontinuation of denosumab results in high-turnover bone loss and increased fracture risk,” Sabashini ...

Bisphosphonate therapy should continue as long as the patient is able to tolerate therapy or until evidence of a substantial decline in performance status. A serum creatinine measurement should be ...

Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (Let): 12 mos BMD results ...

Randomized phase II study of epirubicin (E) plus cyclophosphamide (C) vs. weekly paclitaxel (P) as primary systemic therapy (PST) in patients (pts) with stage II and III breast cancer (BC) ...

Zoledronic acid injection is indicated for the treatment of hypercalcemia of malignancy and for the treatment of multiple myeloma and bone metastases of solid tumors, in conjunction with standard ...

Gonadotropin-releasing-hormone (GnRH) agonists are routinely used to manage recurrent nonmetastatic prostate cancer, but the therapy results in hypogonadism, which has adverse consequences including ...

Zometa (zoledronic acid) is a brand-name IV infusion that’s prescribed to treat high calcium levels due to cancer and help prevent bone problems caused by certain types of cancer. As with other drugs, ...

Yearly infusion of zoledronic acid is as good as, and possibly even better than, daily oral risedronate for prevention and treatment of bone loss as a result of glucocorticoid therapy, according to ...

Reclast (zoledronic acid or zoledronate) is approved by the Food and Drug Administration (FDA) to treat and prevent osteoporosis in males, females after menopause, and people taking glucocorticoids.

The U.S. Food and Drug Administration (FDA) has approved Reclast® (zoledronic acid) Injection, the first and only once-yearly treatment for postmenopausal osteoporosis. Approximately 8 million women ...